Background: Renal ischemia and hypertension have been suggested to be involved in the progression of renal diseases. Recently, we developed a model of accelerated major histocompatibility complex-independent renal injury, where high-renin hypertension aggravates functional and morphological changes induced by ischemia/reperfusion (I/R). In this model, we evaluated the effect of immunosuppressant mycophenolate mofetil (MMF) to test its capability to slow the progression of accelerated nephropathy. Methods: 34 anesthetized uninephrectomized hypertensive transgenic (mREN2)27 rats (TGR) received a clamp on the renal pedicle for 45 min. Animals were treated with MMF 10 mg/kg/day (n = 10), 20 mg/kg/day (n = 10) or placebo (n = 10) orally via gavage for 12 weeks. Four animals were sham operated and not treated. Proteinuria and blood pressure were evaluated throughout the experiment. At the end of the experiment, kidney function was evaluated and kidneys harvested for morphological analysis and immunohistochemistry (CD4+, CD8+ lymphocytes and specific rat monocyte/macrophage marker ED-1+ cells). Results: At week 12, both MMF-treated groups had lower proteinuria as compared to the placebo group (MMF 10: 22.4 ± 9.8, MMF 20: 20.9 ± 5.6 vs. 126.7 ± 35.8; p < 0.01; sham 28.1 ± 1.4 mg/day) and reduced glomerulosclerosis (MMF 10: 11.4 ± 7.8, MMF 20: 5.2 ± 2.7 vs. 20.9 ± 10.9; p < 0.05; sham 15.7 ± 9.2%). There were no differences in systolic blood pressure among groups. MMF-treated rats had lower CD4+ (MMF 10: 61.2 ± 46.4, MMF 20: 29.3 ± 18.2 vs. 125.3 ± 42.8; p < 0.01, sham 84.9 ± 6.1 cells/field of view) and CD8+ (MMF 10: 13.7 ± 10.2, MMF 20: 10.0 ± 8.1 vs. 37.8 ± 14.3; p < 0.01; sham: 31.8 ± 7.6 cells/field of view) lymphocytes infiltration and ED-1 macrophages infiltration (MMF 10: 5.5 ± 6.4, MMF 20: 2.5 ± 2.8 vs. 16.7 ± 4.1; p < 0.01; sham 12.2 ± 4.6 cells/field of view) than placebo-treated rats. Conclusion: Our results thus support the hypothesis about the key role of immune mechanisms in progression of chronic nephropathies.

Keywords:
Ischemia/reperfusion injury, Mycophenolate mofetil, Transgenic rat, Chronic allograft nephropathy, Hypertension
This content is only available via PDF.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.